Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice.
暂无分享,去创建一个
Makoto Naito | Tatsuhiko Kodama | Peter Libby | P. Libby | T. Kodama | J. Witztum | Jie Pan | M. Chin | G. Sukhova | S. Tsimikas | Michael L Lu | Y. Wada | Takashi Yamamoto | M. Naito | G. Shi | Joseph L Witztum | Galina K Sukhova | Yaou Zhang | Jie-Hong Pan | Youichiro Wada | Takashi Yamamoto | Sotirios Tsimikas | Yasuhiko Sakara | Michael T Chin | Guo-Ping Shi | Yaou Zhang | Yasuhiko Sakara | Michael L. Lu
[1] Peter Libby,et al. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.
[2] K. Schäkel,et al. The CD16+ (FcγRIII+) Subset of Human Monocytes Preferentially Becomes Migratory Dendritic Cells in a Model Tissue Setting , 2002, The Journal of experimental medicine.
[3] G. Hansson. Regulation of Immune Mechanisms in Atherosclerosis , 2001, Annals of the New York Academy of Sciences.
[4] P. Libby,et al. Inflammation and Atherothrombosis , 2001, Annals of the New York Academy of Sciences.
[5] R. Locksley,et al. Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S. , 2001, Immunity.
[6] Steffen Jung,et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. , 2001, The Journal of clinical investigation.
[7] P. Libby,et al. Drilling for oxygen: angiogenesis involves proteolysis of the extracellular matrix. , 2001, Circulation research.
[8] K. Moulton. ArePlaque angiogenesis and atherosclerosis , 2001 .
[9] P. Libby,et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. , 2001, The Journal of clinical investigation.
[10] M. Dake,et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression , 2001, Nature Medicine.
[11] K. Moulton. Plaque angiogenesis and atherosclerosis. , 2001, Current atherosclerosis reports.
[12] Mark L. Benson,et al. Isolation of vascular smooth muscle cells from a single murine aorta. , 2001, Methods in cell science : an official journal of the Society for In Vitro Biology.
[13] H. Tschesche,et al. Matrix Metalloproteinases Collagenase-2, Macrophage Elastase, Collagenase-3, and Membrane Type 1-Matrix Metalloproteinase Impair Clotting by Degradation of Fibrinogen and Factor XII* , 2000, The Journal of Biological Chemistry.
[14] S. Weiss,et al. Regulation of Elastinolytic Cysteine Proteinase Activity in Normal and Cathepsin K–Deficient Human Macrophages , 2000, The Journal of experimental medicine.
[15] A M Zeiher,et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. , 2000, Circulation research.
[16] P. Libby. Changing concepts of atherogenesis , 2000, Journal of internal medicine.
[17] Y. Yazaki,et al. An in vitro coculture model of transmigrant monocytes and foam cell formation. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[18] P. Libby,et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. , 1999, The Journal of clinical investigation.
[19] P. Libby,et al. CD1 expression in human atherosclerosis. A potential mechanism for T cell activation by foam cells. , 1999, The American journal of pathology.
[20] J. Caillaud,et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. , 1999, Circulation.
[21] P. Libby,et al. Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[22] P. Libby,et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.
[23] M A Konerding,et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.
[24] G. Dranoff,et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.
[25] A. Rudensky,et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. , 1999, Immunity.
[26] T. Luther,et al. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. , 1998, Blood.
[27] P. Carmeliet,et al. Reduced transplant arteriosclerosis in plasminogen-deficient mice. , 1998, The Journal of clinical investigation.
[28] É. Allaire,et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. , 1998, The Journal of clinical investigation.
[29] P. Libby,et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.
[30] P. Libby,et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.
[31] Dean Y. Li,et al. Elastin is an essential determinant of arterial morphogenesis , 1998, Nature.
[32] T. Kodama,et al. Immunohistochemical evidence for a macrophage scavenger receptor in Mato cells and reactive microglia of ischemia and Alzheimer's disease. , 1998, Biochemical and biophysical research communications.
[33] P. Carmeliet,et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.
[34] A. Mcnicol,et al. Organisation of basement membrane components in the human adult and fetal pituitary gland and in pituitary adenomas , 1997, Virchows Archiv.
[35] G. D. De Meyer,et al. Mechanisms of Neointima Formation—Lessons from Experimental Models , 1997, Vascular medicine.
[36] P. Carmeliet,et al. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. , 1997, The Journal of clinical investigation.
[37] H. Chapman,et al. Emerging roles for cysteine proteases in human biology. , 1997, Annual review of physiology.
[38] S. Shapiro,et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[39] A. Daugherty,et al. Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease progression. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[40] R. Virmani,et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.
[41] C. Rackley,et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. , 1996, American heart journal.
[42] S. E. Brodie. New York, New York, USA , 1996 .
[43] S. Young,et al. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[44] S. Weiss,et al. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Isner,et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. , 1995, Circulation.
[46] P. Libby,et al. Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque , 1995, Journal of cardiovascular pharmacology.
[47] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[48] D K Burns,et al. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. , 1994, The Journal of clinical investigation.
[49] R. Hammer,et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.
[50] M. Davies,et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. , 1993, British heart journal.
[51] A. J. Valente,et al. Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. , 1992, Circulation.
[52] R. Mason,et al. The specificity and elastinolytic activities of bovine cathepsins S and H. , 1992, Archives of biochemistry and biophysics.
[53] D. Rich,et al. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. , 1992, The Journal of biological chemistry.
[54] A. Henney,et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[55] P. Libby,et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[56] R. Maciewicz,et al. A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen. , 1988, The Biochemical journal.
[57] S. Gordon,et al. F4/80, a monoclonal antibody directed specifically against the mouse macrophage , 1981, European journal of immunology.